Drug Profile
Research programme: farnesoid X receptor agonists - Poxel
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Poxel
- Developer ENYO Pharma; Poxel
- Class
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Hepatitis-B in France (PO)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in France
- 21 Jul 2016 Preclinical development is ongoing for Type-2 diabetes mellitus in France (Poxel pipeline, July 2016)